139 related articles for article (PubMed ID: 36550575)
1. The presence of SARS-CoV-2 in multiple clinical specimens of a fatal case of COVID-19: a case report.
Sokolovska L; Terentjeva-Decuka A; Cistjakovs M; Nora-Krukle Z; Gravelsina S; Vilmane A; Vecvagare K; Murovska M
J Med Case Rep; 2022 Dec; 16(1):484. PubMed ID: 36550575
[TBL] [Abstract][Full Text] [Related]
2. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
[TBL] [Abstract][Full Text] [Related]
4. [SARS-CoV-2 and Microbiological Diagnostic Dynamics in COVID-19 Pandemic].
Erensoy S
Mikrobiyol Bul; 2020 Jul; 54(3):497-509. PubMed ID: 32755524
[TBL] [Abstract][Full Text] [Related]
5. Evolution of severe acute respiratory syndrome coronavirus 2 RNA test results in a patient with fatal coronavirus disease 2019: a case report.
Shao C; Liu H; Meng L; Sun L; Wang Y; Yue Z; Kong H; Li H; Weng H; Lv F; Jin R
Hum Pathol; 2020 Jul; 101():82-88. PubMed ID: 32437706
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
7. Persistent but dysfunctional mucosal SARS-CoV-2-specific IgA and low lung IL-1β associate with COVID-19 fatal outcome: A cross-sectional analysis.
Ruiz MJ; Siracusano G; Cottignies-Calamarte A; Tudor D; Real F; Zhu A; Pastori C; Capron C; Rosenberg AR; Temperton N; Cantoni D; Liao H; Ternette N; Moine P; Godement M; Geri G; Chiche JD; Annane D; Cramer Bordé E; Lopalco L; Bomsel M
Front Immunol; 2022; 13():842468. PubMed ID: 36248831
[TBL] [Abstract][Full Text] [Related]
8. Presence of SARS-CoV-2 RNA in the Cornea of Viremic Patients With COVID-19.
Casagrande M; Fitzek A; Spitzer MS; Püschel K; Glatzel M; Krasemann S; Nörz D; Lütgehetmann M; Pfefferle S; Schultheiss M
JAMA Ophthalmol; 2021 Apr; 139(4):383-388. PubMed ID: 33475692
[TBL] [Abstract][Full Text] [Related]
9. [Shedding of SARS-CoV-2 Virus in COVID-19 Patients and Neutralizing Antibody Level].
Ayhancı T; Toptan H; Özer YE; Uzar S; Enül H; Adıay C; Sarac F; Dheir H; Köroğlu M; Hasöksüz M; Altındiş M
Mikrobiyol Bul; 2022 Jul; 56(3):416-431. PubMed ID: 35960235
[TBL] [Abstract][Full Text] [Related]
10. Detection of SARS-CoV-2 in Fecal Samples From Patients With Asymptomatic and Mild COVID-19 in Korea.
Park SK; Lee CW; Park DI; Woo HY; Cheong HS; Shin HC; Ahn K; Kwon MJ; Joo EJ
Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1387-1394.e2. PubMed ID: 32534042
[TBL] [Abstract][Full Text] [Related]
11. The kinetics of viral load and antibodies to SARS-CoV-2.
Sun J; Tang X; Bai R; Liang C; Zeng L; Lin H; Yuan R; Zhou P; Huang X; Xiong Q; Peng J; Cui F; Ke B; Su J; Liu Z; Lu J; Tian J; Sun R; Ke C
Clin Microbiol Infect; 2020 Dec; 26(12):1690.e1-1690.e4. PubMed ID: 32898715
[TBL] [Abstract][Full Text] [Related]
12. Necessity for detection of SARS-CoV-2 RNA in multiple types of specimens for the discharge of the patients with COVID-19.
Tong Y; Bao A; Chen H; Huang J; Lv Z; Feng L; Cheng Y; Wang Y; Bai L; Rao W; Zheng H; Wu Z; Qiao B; Zhao Z; Wang H; Li Y
J Transl Med; 2020 Nov; 18(1):411. PubMed ID: 33138834
[TBL] [Abstract][Full Text] [Related]
13. Characteristics and roles of severe acute respiratory syndrome coronavirus 2-specific antibodies in patients with different severities of coronavirus 19.
Huang Z; Chen H; Xue M; Huang H; Zheng P; Luo W; Liang X; Sun B; Zhong N
Clin Exp Immunol; 2020 Nov; 202(2):210-219. PubMed ID: 32706417
[TBL] [Abstract][Full Text] [Related]
14. The host immune response of a discharged COVID-19 patient with twice reemergence of SARS-CoV-2: a case report.
Zao X; Zhou Y; Liang Y; Cao X; Chen H; Li X; Ye Y
BMC Infect Dis; 2021 Sep; 21(1):991. PubMed ID: 34556058
[TBL] [Abstract][Full Text] [Related]
15. Clinical and virological data of the first cases of COVID-19 in Europe: a case series.
Lescure FX; Bouadma L; Nguyen D; Parisey M; Wicky PH; Behillil S; Gaymard A; Bouscambert-Duchamp M; Donati F; Le Hingrat Q; Enouf V; Houhou-Fidouh N; Valette M; Mailles A; Lucet JC; Mentre F; Duval X; Descamps D; Malvy D; Timsit JF; Lina B; van-der-Werf S; Yazdanpanah Y
Lancet Infect Dis; 2020 Jun; 20(6):697-706. PubMed ID: 32224310
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Open label Phase-II Clinical Trial with or without Infusion of Plasma from Subjects after Convalescence of SARS-CoV-2 Infection in High-Risk Patients with Confirmed Severe SARS-CoV-2 Disease (RECOVER): A structured summary of a study protocol for a randomised controlled trial.
Janssen M; Schäkel U; Djuka Fokou C; Krisam J; Stermann J; Kriegsmann K; Haberbosch I; Novotny JP; Weber S; Vehreschild M; Bornhäuser M; Bullinger L; Schmitt M; Liebregts T; Dreger P; Lorenz HM; Plaszczyca A; Bartenschlager R; Müller B; Kräusslich HG; Halama N; Jäger D; Schlenk RF; Leo A; Meuer S; Weigand MA; Motsch J; Merle U; Denkinger CM; Müller-Tidow C
Trials; 2020 Oct; 21(1):828. PubMed ID: 33023671
[TBL] [Abstract][Full Text] [Related]
17. Impact of dexamethasone on SARS-CoV-2 concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study.
Mühlemann B; Thibeault C; Hillus D; Helbig ET; Lippert LJ; Tober-Lau P; Schwarz T; Müller MA; ; Witzenrath M; Suttorp N; Sander LE; Drosten C; Jones TC; Corman VM; Kurth F
Clin Microbiol Infect; 2021 Oct; 27(10):1520.e7-1520.e10. PubMed ID: 34139335
[TBL] [Abstract][Full Text] [Related]
18. Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies.
Guo X; Zeng L; Huang Z; He Y; Zhang Z; Zhong Z
Front Immunol; 2020; 11():1936. PubMed ID: 32849650
[No Abstract] [Full Text] [Related]
19. Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients.
Ouoba S; Okimoto M; Nagashima S; Kitahara Y; Miwata K; Ko K; E B; Sugiyama A; Takahashi K; Sakaguchi T; Takafuta T; Tanaka J
J Med Virol; 2022 Apr; 94(4):1734-1737. PubMed ID: 34897741
[TBL] [Abstract][Full Text] [Related]
20. Quantitative detection of SARS-CoV-2 RNA in nasopharyngeal samples from infected patients with mild disease.
Bustos P; Tambley C; Acevedo A; Andrade W; Leal G; Vidal D; Roldán F; Fasce R; Ramírez E
J Med Virol; 2021 Apr; 93(4):2439-2445. PubMed ID: 33368332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
